[CLSTR]
< Back to situations

We’ll email you as it develops, and you can follow the whole thread from day one.

[SITUATION] · [ACTIVE]

2 clusters · 5 sources · 2 days · First seen · Last updated

Categories: BUSINESS

GLP-1 drugs market expansion

Entities: Novo Nordisk · Brazil · BIC · CoBank · GLP-1 receptor agonists

Overview

In early August 2026, reports highlighted that GLP‑1 weight‑loss injections such as Ozempic, Wegovy, Mounjaro and Zepbound generated over US$ 40 billion in sales in 2024. The rapid uptake altered consumer habits, prompting demand for smaller‑portion desserts in Brazil and spurring design innovations in injection pens to improve ease of use, though cost remains a barrier.

Two days later, a CoBank analysis warned that the growing use of GLP‑1 therapies could cut U.S. food and beverage spending by $30 billion by 2030 and $55 billion by 2034, potentially shrinking grocery baskets by up to 31 % among active users. Market forecasts projected the global GLP‑1 market to rise from $58.4 billion in 2025 to $212.73 billion by 2035, driven by expanding indications beyond diabetes and strong adoption in the United States.

Timeline

  1. 1 day ago

    [BUSINESS] 3 sources
    GLP-1 drugs set to reshape sugar demand and spur $2 trillion market growth

    CoBank warns GLP‑1 drugs could cut U.S. sugar demand and food spending, while a separate forecast projects the global GLP‑1 market to grow to $212 billion by 2035.

  2. 3 days ago

    [BUSINESS] 2 sources
    GLP‑1 weight‑loss drugs spur rise of mini desserts and pen design

    GLP‑1 weight‑loss injections, now a $40 bn market, are driving demand for mini desserts in Brazil and prompting innovative, yet costly, pen designs.

Sources

dreamnews.jp · leianoticias.com.br · meioemensagem.com.br · mococa.com.br · perishablenews.com